^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SOCS1 mutation

    i
    Other names: SOCS1, Suppressor Of Cytokine Signaling 1, SSI-1, TIP3, JAB, STAT-Induced STAT Inhibitor 1, Tec-Interacting Protein 3, TIP-3, Cytokine-Inducible SH2 Protein 1, STAT Induced SH3 Protein 1, JAK-Binding Protein, CISH1, CIS1
    Entrez ID:
    8651
    Related biomarkers:
    Expression
    1year
    CD23 positive, BCL2 rearrangement-negative germinal centre lymphomas (PubMed, Pathologie (Heidelb))
    Genetically, this lymphoma group is characterised by a high rate of either STAT6 or SOCS1 mutations.The ICC classification took this development into account by introducing the provisional entity CD23 positive, BCL2 rearrangement-negative germinal centre lymphoma. Further studies must now show how exactly this entity can be defined (combination of morphology, immunohistochemical phenotype, focus on genetic alterations) in order to pave the way towards a uniform classification and a better clinical characterisation of these cases - especially with regard to possible new therapeutic treatment options.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT6 (Signal transducer and activator of transcription 6) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    BCL2 positive • BCL2 rearrangement • SOCS1 mutation • BCL2 translocation
    1year
    Spectrum and Clinical Features of Gene Mutations in Chinese Follicular Lymphoma (ASH 2023)
    For patients who received R-CHOP-like regimens, the multivariate COX proportional hazard modeling identified TP53, TNFAIP3, and SOCS1 mutations as independent risk factors of PFS (HR 6.76, 95% CI 1.81 to 25.18, p =0.004; HR 3.68, 95% CI 1.06 to 12.82, p =0.041; HR 5.07, 95% CI 1.81 to 21.73, p =0.029). Our study depicted genomic characterization of real-world Chinses FL patients and demonstrated TP53, TNFAIP3 and SOCS1 mutations can help identify high-risk patients.
    Clinical • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CARD11 (Caspase Recruitment Domain Family Member 11) • NOTCH3 (Notch Receptor 3) • TNFAIP3 (TNF Alpha Induced Protein 3) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1)
    |
    NOTCH3 mutation • PRDM1 mutation • SOCS1 mutation
    |
    Rituxan (rituximab)
    over1year
    Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas. (PubMed, Acta Neuropathol)
    Correspondingly, deconvolution of bulk RNASeq data revealed elevated M2-macrophage, T-regulatory cell, mast cell and monocyte fractions in EBV PCNSL. In addition to novel insights into the pathobiology of EBV PCNSL, the data provide the rationale for the exploration of targeted therapies including JAK-, NOTCH- and CD70-directed approaches.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • CD70 (CD70 Molecule) • STING (stimulator of interferon response cGAMP interactor 1) • PIM1 (Pim-1 Proto-Oncogene) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    SOCS1 mutation
    over1year
    Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop. (PubMed, Am J Clin Pathol)
    Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • TNFAIP3 (TNF Alpha Induced Protein 3) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT6 (Signal transducer and activator of transcription 6) • ZNF217 (Zinc Finger Protein 217) • RIT1 (Ras Like Without CAAX 1)
    |
    FGFR2 mutation • SOCS1 mutation
    over1year
    A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA. (EHA 2023)
    Treatment for rrPMBCL can include targeted sequential immunotherapy. If a PD1 tumor reduction regimen achieves PR or higher, patients should begin CART as soon as possible. B2M mutation-positive, SOCS1-positive patients can benefit from targeted sequential immunotherapy.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    B2M (Beta-2-microglobulin) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT6 (Signal transducer and activator of transcription 6)
    |
    ERBB3 mutation • B2M mutation • SOCS1 mutation
    over1year
    GENE EXPRESSION PROFILING OF T(14;18)-NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESIS (ICML 2023)
    GEP identified two distinct groups within t(14;18)-neg FL, indicating different stages of differentiation of the neoplastic B cells. FLnegmut shows activation of STAT6 pathway through upregulation of CD23 and IL4R and by enrichment in GSEA and correlates with CD23 expression. Constitutive activation of STAT6 and consequent upregulation of CD23 prevent ongoing B cell differentiation in FLnegmut, precluding the cells from exiting the GC and adopting the state of activated B cell.
    IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF17 (TNF Receptor Superfamily Member 17) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • S100A8 (S100 Calcium Binding Protein A8) • IRF4 (Interferon regulatory factor 4) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • TYK2 (Tyrosine Kinase 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CD40 (CD40 Molecule) • FCGR1A (Fc Fragment Of IgG Receptor Ia) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • IL4 (Interleukin 4) • FCER2 (Fc Fragment Of IgE Receptor II) • FCRLA (Fc Receptor Like A) • IL4R (Interleukin 4 Receptor) • SLAMF7 (SLAM Family Member 7) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    SOCS1 mutation
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    almost2years
    Structural Analysis and Conformational Dynamics of SOCS1 Gene Mutations Involved in Diffuse Large B-Cell Lymphoma. (PubMed, Gene)
    Based on all these computational predictions, this study finds that certain mutations, particularly S116N, have a destabilising and robust effect on the SOCS1 protein. These results can be used to learn more about the importance of SOCS1 mutations in DLBCL patients and to develop new ways to treat DLBCL.
    Journal
    |
    SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    SOCS1 mutation
    over2years
    Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma. (PubMed, Biomark Res)
    There was a positive correlation between transcripts of IL-2R and immune checkpoint expressions including PD-1 and CTLA-4. Our findings identified that dynamic change of sIL-2R, with this simple and easy detection method in peripheral blood, had long-term prognostic effect and specific relation to microenvironment alterations in DLBCL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    RET (Ret Proto-Oncogene) • ARID1A (AT-rich interaction domain 1A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • KMT2D (Lysine Methyltransferase 2D) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    ARID1A mutation • RET mutation • MYD88 mutation • KMT2D mutation • CTLA4 expression • LYN mutation • SOCS1 mutation
    almost3years
    Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. (PubMed, Cancers (Basel))
    Patients with low MTV and favorable mutational profile (9%) had the lowest risk, while the remaining patients constituted the intermediate-risk group (76%). The resulting model stratified patients among three groups with 2-year PFS of 100%, 82%, and 42%, respectively (p < 0.001).
    Retrospective data • Journal
    |
    CREBBP (CREB binding protein) • EP300 (E1A binding protein p300) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    SOCS1 mutation
    3years
    Combination of two monoclonal antibodies with SOCS1 N- and C-terminal binding sites to address SOCS1 status in B cells and B-cell lymphoma. (PubMed, Eur J Haematol)
    Anti-SOCS1 antibody 4H1 may be useful in a molecular setting, but is disqualified as an immunohistochemical diagnostic tool due to its very broad non-specific binding.
    Journal
    |
    SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    SOCS1 mutation
    3years
    Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations (ASH 2021)
    We have developed a novel immunogenomic platform to define the role of tumor-cell intrinsic alterations on the immune landscape of DLBCL. Confirmatory studies using in vitro and in vivo models validated the effect of key oncogenes and TSGs on the tumor microenvironment, and suggest these candidate genes may impact response to CBT in DLBCL.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin) • CD4 (CD4 Molecule) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    ATM mutation • PD-L1 amplification • SOCS1 mutation
    over3years
    [VIRTUAL] TRACKING CLONAL HEMATOPOIESIS IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (EHA 2021)
    Conclusion CH can be observed in the cHL tissue, can originate the tumor clone and can propagate to large part of its microenvironment. Considering that both tumor cells and the microenvironment supporting its growth play key roles in cHL pathogenesis, CH might contribute to the development of this lymphoma and influence its prognosis.
    Clinical • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT6 (Signal transducer and activator of transcription 6)
    |
    TP53 mutation • KRAS mutation • NPM1 mutation • DNMT3A mutation • DNMT3A R882H • DNMT3A R882 • KRAS G60D • SOCS1 mutation